Cannabix Technologies Adds Dr. Randall Purves as Scientific Advisor
May 13 2019 - 08:38AM
InvestorsHub NewsWire
501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Adds Dr. Randall Purves as Scientific
Advisor
The Cannabix Marijuana Breathalyzer
system
is being developed to give law enforcement and employers a tool to
enforce public safety.
Vancouver, British Columbia -- May 13,
2019 -- InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:
BLO) (OTC PINK: BLOZF) (the “Company”) is
pleased to announce that Dr. Randy Purves has been appointed as a
Scientific Advisor to Cannabix Technologies Inc. Dr. Purves is one
of the world’s foremost experts in the development of FAIMS
(high-field asymmetric waveform ion mobility spectrometry)
instrumentation and applications. Dr. Purves is a pioneer in
developing FAIMS technology and in 2001 he co-founded Ionalytics,
an instrument company specializing in FAIMS devices for use with
mass spectrometry. Ionalytics was acquired by Thermo Electron (now
Thermo Fisher Scientific) in 2005 and Dr. Purves was part of the
Thermo team involved with the commercial release of an integrated
FAIMS product for use with a TSQ Quantum mass spectrometer in
2006.
Dr. Randy Purves obtained his Ph.D. in
Analytical Chemistry from the University of Alberta. Dr. Purves has
over 25 years of experience working with mass spectrometry, which
includes working in drug metabolism at Merck Frosst. Dr.
Purves is an expert in the development and application of FAIMS,
having co-authored 45 refereed publications in FAIMS and
differential mobility spectrometry (DMS) in general. Dr. Purves is
an adjunct professor in the College of Pharmacy and Nutrition at
the University of Saskatchewan and continues to collaborate with
Thermo Fisher Scientific on further enhancing FAIMS technology for
mass spectrometry based applications. A primary interest of
Dr. Purves is to use his expertise in FAIMS and small molecule
analysis to improve quantification methods of analytes in
challenging matrices.
Dr. Raj Attariwala, Cannabix’s Chief
Scientific Officer, states, “Dr. Purves has deep, unparalleled
experience with FAIMS technology that will be a tremendous benefit
to our scientific team and technology
development.”
The Company has
granted Dr. Purves 150,000 stock options exercisable at $1.50 for a
period of 2 years.
About Cannabix
Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects previous usage from days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment by THC can be
hazardous.
We seek Safe
Harbor.
On behalf of the
Board of
Directors
“Rav
Mlait”
CEO
Cannabix Technologies
Inc.
For further
information, contact the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this
release.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
information that involves various risks and uncertainties regarding
future events. Such forward-looking information can include without
limitation statements based on current expectations involving a
number of risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking
statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Mar 2023 to Mar 2024